© 2025 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
IQVIA's Michael Kleinrock Shares Why Smaller Manufacturers Are Investing in Biosimilar Development
Skylar Jeremias
March 12 2023
Better familiarity with biosimilars is enabling government agencies to reevaluate their approval requirements and encouraging smaller manufacturers to invest in biosimilar development, said Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.
Celltrion Publishes Data on Maintenance Therapy Using Infliximab Biobetter
Skylar Jeremias
March 6 2023
Congress of the European Crohn's and Colitis Organisation (ECCO)
At the European Crohn’s and Colitis Organisation congress, Celltrion Healthcare shared positive safety and efficacy data on maintenance therapy including its infliximab biobetter allowing for subcutaneous administration, Remsima SC.
Access 2023: FDA’s Dr Jacqueline Corrigan-Curay Gives Updates on Biosimilar, Generic User Fee Programs
Skylar Jeremias
February 22 2023
Jacqueline Corrigan-Curay, MD, JD, principal deputy center director of the FDA's Center for Drug Evaluation and Research, gave a keynote presentation at Access 2023 on how the Biosimilar User Fee Act and the Generic Drug User Fee Act have developed over the last year.
IGBA Panelists Discuss the Global Reputation of Biosimilars, Generics
Skylar Jeremias
February 21 2023
Panelists at the annual meeting of the International Generic and Biosimilar Medicines Association (IGBA) offered insight into the current state of the global biosimilar and generic markets and why government agencies need to leverage these medicines to address challenges in the pharmaceutical space.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
Skylar Jeremias
February 19 2023
COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Access 2023: Panelists Weigh In on the Many Factors Influencing Biosimilar Uptake Patterns
Skylar Jeremias
February 16 2023
Two presentations and a panel discussion at the annual meeting of the Association for Accessible Medicines (Access 2023) went over the current state of biosimilar uptake and the factors that help determine whether a biosimilar will experience good adoption rates.
Access 2023: Mark Cuban Teases Adding Biosimilars to Online Pharmacy, Champions Generics
Skylar Jeremias
February 15 2023
At the annual meeting of the Association for Accessible Medicines (Access 2023), Shark Tank’s Mark Cuban explained his dedication to and the inner workings of his online pharmacy that provides generic drugs to patients for significantly lower prices than traditional pharmacies.
What Will Be the Major Drivers Behind IQVIA's Predicted Biosimilars Uptake, Savings?
Skylar Jeremias
February 14 2023
Adalimumab and ustekinumab biosimilars aren't the only factors that will drive biosimilar adoption and savings through 2023, according to Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.
Dr Michael Chiang: How the National Eye Institute Is Building Confidence in Ophthalmology Biosimilars
Skylar Jeremias
January 15 2023
AAO: American Academy of Ophthalmology
Michael Chiang, MD, director of the National Eye Institute, discusses how his team is working to instill greater confidence in ophthalmology biosimilars among wary ophthalmologists.
